Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | LOXO-338 for the treatment of advanced hematological malignancies

Wojciech Jurczak • 11 Jun 2022
EHA 2022
General LOXO-338 Venetoclax

Wojciech Jurczak, MD, PhD, Jagiellonian University, Krakow, Poland talks on a Phase I study evaluating oral LOXO-338, a selective BCL2 inhibitor, for the treatment of patients with advanced hematological malignancies (NCT05024045). Prof. Jurczak discusses the importance of developing other BCL2 inhibitors and the future implications of this research. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

More from Wojciech Jurczak

1:35
Long-term follow-up of tafasitamab and lenalidomide in R/R DLBCL
Wojciech Jurczak • 10 Jun 2023
3:01
Updates from the BRUIN study – long-term safety of pirtobrutinib in R/R MCL
Wojciech Jurczak • 10 Jun 2023
1:49
Follow-up results of EPCORE NHL-1: subcutaneous epcoritamab in R/R LBCL
Wojciech Jurczak • 10 Jun 2023
1:05
Updates on tafasitamab for the treatment of DLBCL
Wojciech Jurczak • 11 Jun 2022

Related Videos

4:07
Pooled fecal allogeneic microbiotherapy to treat refractory gastrointestinal acute GvHD
Florent Malard • 11 Apr 2024
5:23
Current and emerging treatment approaches for steroid-refractory acute & chronic GvHD
Mohamad Mohty • 17 Apr 2024
2:00
HHV-6 reactivation after haploidentical transplantation with PTCy & ATG: incidence and risk factors
Rémy Duléry • 15 Apr 2024
1:41
The consequences of regulatory changes on access to devices and reagents needed for graft processing
Christian Chabannon • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals